SAGE Therapeutics Initiates Exploratory Study of SAGE-547

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SAGE Therapeutics Initiates Exploratory Study of SAGE-547 in Essential Tremor

CAMBRIDGE, Mass., Oct. 23, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq: SAGE ) today announced dose initiation of the first patient in a single-center Phase 2a clinical trial of SAGE-547, an allosteric modulator of GABA A receptors, in patients with essential tremor. This trial is designed to evaluate the safety, tolerability, pharmacokinetics and activity of SAGE-547 in patients with essential tremor, a neurological disorder that causes involuntary, rhythmic shaking with no known cause. The trial is being conducted under a newly accepted Investigational New Drug filing.

"SAGE-547 is a molecule with an attractive, acute therapeutic profile well-suited for exploring the impact of its mechanism on many GABA-related disorders, including essential tremor," said Jeffrey Jonas, M.D., chief executive officer of SAGE Therapeutics. "There is clinical and preclinical evidence that GABA receptor dysfunction in the brain may be a factor in essential tremor. We plan to use data from this exploratory study, if positive, to help model and guide the design of a second-generation molecule for the chronic treatment of this debilitating disease."

This Phase 2a trial is a double blind, proof-of-concept study of SAGE-547 in patients who have a diagnosis of essential tremor with symptoms clearly present in at least one upper limb. The trial is expected to enroll 24 adult patients with essential tremor for at least 2 years, a score of ≥ 2 for at least one upper limb maneuver as measured by The Essential Tremor Rating Scale (TETRAS) performance subscale, and who are not currently taking medication for their tremor or are on a stable dose of medication for at least 28 days prior to enrollment. This trial is designed to provide clear data regarding the safety and tolerability of SAGE-547 using ratings and mechanical measures of motor activity designed to rapidly yield unambiguous endpoints. The activity of SAGE-547 will be assessed via physician examination, transducer measurement of tremor amplitude and full TETRAS and TETRAS performance subscale measurements. Patients will be administered either SAGE-547 or placebo intravenously for 12 hours on Day 1 and Day 10 in a double blind cross-over manner. Patients will be monitored for up to 30 days following treatment.

"Current treatments for essential tremor are only moderately effective, as most reduce but do not resolve tremor levels in the majority of treated patients," said Stephen Kanes, M.D., Ph.D., chief medical officer of SAGE Therapeutics. "There remains a dire need for new therapies for these patients with persistent, visible tremor that significantly impacts their daily life."

About SAGE-547

SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABA A receptors. GABA A receptors are widely regarded as validated drug targets for a variety of CNS disorders, with decades of research and multiple approved drugs targeting these receptor systems. SAGE-547 is an intravenous agent in Phase 1/2 clinical development as an adjunctive therapy, a therapy combined with current therapeutic approaches, for the treatment of super-refractory status epilepticus (SRSE), as a treatment for essential tremor.

About Essential Tremor

Essential tremor (ET) is a common neurological condition that affects an estimated 10 million Americans and millions more worldwide. ET causes a rhythmic trembling of the hands, head, voice, legs or trunk. Symptoms generally evolve over time and are both visible and persistent following onset, which commonly occurs either between 15-20 or 50-70 years of age. First-line treatments for essential tremor include the anticonvulsant primidone and the β-adrenergic blocker propranolol. All current treatments for ET are only moderately effective, reducing, though not resolving, tremor amplitudes in about 50% of the patients. In addition, one out of three patients abandons treatment due to side effects or poor efficacy.

About SAGE Therapeutics

SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders. For more information, please visit www.sagerx.com .

Forward-Looking Statements

This release contains forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward looking statements. For example SAGE's future expectations, plans and prospects, including without limitation, SAGE's expectations regarding the potential safety, pharmacological effect and efficacy of SAGE-547 as a treatment for SRSE and essential tremor, the expected development pathway for its other product candidates and its expectations with respect to the timing and success of its clinical trials, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In particular it should be noted that the initial data reported from the ongoing Phase 1/2 clinical trial of SAGE-547 for SRSE are preliminary in nature and that this SAGE-547 clinical trial has not been completed. The preliminary data may change as additional data is released and such preliminary data may not be repeated or observed in ongoing or future studies involving SAGE-547 or our other product candidates. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, SAGE's ability to successfully demonstrate the efficacy and safety of its product candidates, the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, SAGE's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, SAGE's ability to manage operating expenses, SAGE's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, SAGE's dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in the final prospectus related to SAGE's initial public offering filed with the Securities and Exchange Commission pursuant to Rule 424(b) of the Securities Act of 1933, as amended, as well as discussions of potential risks, uncertainties, and other important factors in SAGE's subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent SAGE's views only as of today and should not be relied upon as representing its views as of any subsequent date. SAGE explicitly disclaims any obligation to update any forward-looking statements.

Media Contact: Dan Budwick, Pure Communications 973-271-6085 Investor Contact: Monique Allaire, Pure Communications 781-631-0759

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 51

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036

Updated Category News Views 222

A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...

Continue Reading
BioArctic's Q3 Call Puts Leqembi Economics Under Watch

Updated Category News Views 32

One Date, Several Unanswered Questions November 25 lands with an unusually clean checklist for BioArctic watchers: results arrive at 8:00 a.m. CET, then management takes the floor at 9:30 a.m. CET. That is the whole immediate event, and it matters because this is not a company investors can sensibly judge by a single headline or a vague promise about neuroscience....

Continue Reading
Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 0

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 69

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 189

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 135

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 197

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading

Top 5 Most Recently Viewed Articles

Shell plc Announces Strategic Share Buybacks Amid Market Moves

Updated Category News Views 250

Shell plc Engages in Significant Share Buybacks Transaction in Own Shares Shell plc, a global leader in energy and petrochemical sectors, has undertaken a strategic initiative involving the purchase of its own shares for cancellation to optimize its capital structure. This decision aligns with the company’s broader strategy to enhance shareholder value through various...

Continue Reading
CSL Seqirus Strengthens Pandemic Readiness with New BARDA Award

Updated Category News Views 280

CSL Seqirus Receives Significant BARDA Award CSL Seqirus has recently received a noteworthy award from the Biomedical Advanced Research and Development Authority (BARDA). This grant is aimed at furthering the company's capabilities in preparing for potential pandemic situations through the development of avian influenza vaccines. The need for preparedness in public health...

Continue Reading
Navient’s Third Quarter Results: Financial Performance Insights

Updated Category News Views 86

Navient Announces Third Quarter 2024 Financial Results HERNDON, Va. — Navient (Nasdaq: NAVI) shared its third quarter financial results for 2024, showcasing the company’s ongoing commitment to providing innovative financial services and solutions. The comprehensive financial results are listed on the company's official site, ensuring transparency and accessibility for...

Continue Reading
Comstock Inc. Unveils Insights from 3Q24 Stakeholder Analysis

Updated Category News Views 169

Comstock Inc. (NYSE: LODE) dropped its Q3 2024 Stakeholder Perception Analysis Report, and you know how these things go—traders squinted at the numbers while trying to decipher what the hell it meant for their investments. So here's the deal: Comstock put out this report to show how its stakeholders felt about its performance and strategy, but really, it raised more...

Continue Reading
GraniteShares Unveils Innovative YieldBOOST Fund-of-Funds ETFs

Updated Category News Views 370

GraniteShares Introduces Unique Fund-of-Funds ETFs GraniteShares, an innovative leader in the ETF space, has recently introduced two new YieldBOOST Fund-of-Funds ETFs. These expansions reflect their commitment to offering cutting-edge investment solutions that cater to the evolving needs of investors. What Are the New ETFs? The two new offerings are the GraniteShares...

Continue Reading